Paramyxovirus vector encoding angiogenesis gene and use thereof
AssigneeDNAVEC Research Inc.
InventorsYOSHIKAZU YONEMITSU, KATSUO SUEISHI, MASAYUKI FUKUMURA, XIAOGANG HOU, MAMORU HASEGAWA, HIDENORI MATSUSAKA, HIROYUKI TSUTSUI
Life of this patent
Estimating the term…
Abstract
The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.
Claims23
1-18. (canceled)
A method for inducing angiogenesis in a subject in need thereof, said method comprising the step of administering to said subject an angiogenic composition comprising a pharmaceutically acceptable carrier and a Paramyxovirus vector comprising a gene encoding fibroblast growth factor 2 (FGF2), thereby inducing angiogenesis in said subject.
A method of treating ischemic tissues in a subject in need thereof, said method comprising the step of administering to said subject an angiogenic composition comprising a pharmaceutically acceptable carrier and a Paramyxovirus vector comprising a gene encoding fibroblast growth factor 2 (FGF2), wherein said method induces angiogenesis in said subject, thereby treating said ischemic tissues in said subject.
Dependencies are inferred from the claim text.